S285: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): 2-YEAR FOLLOW-UP FROM THE CARDINAL STUDY

• A. Röth,
• W. Barcellini,
• S. D’Sa,
• Y. Miyakawa,
• C. M. Broome,
• M. Michel,
• D. J. Kuter,
• B. Jilma,
• T. H. A. Tvedt,
• I. C. Weitz,
• T. Sourdille,
• J. Wang,
• D. S. Vagge,
• K. Kralova,
• F. Shafer,
• M. Wardecki,
• M. Lee,
• S. Berentsen

Affiliations

A. Röth

1 Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

W. Barcellini

2 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

S. D’Sa

3 UCLH Centre for Waldenström’s Macroglobulinemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London, United Kingdom

Y. Miyakawa

4 Thrombosis and Hemostasis Center, Saitama Medical University Hospital, Saitama, Japan

C. M. Broome

5 Division of Hematology, MedStar Georgetown University Hospital, Washington DC, United States of America

M. Michel

6 Henri-Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, UPEC, Créteil, France

D. J. Kuter

7 Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America

B. Jilma

8 Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

T. H. A. Tvedt

9 Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway

I. C. Weitz

10 Keck School of Medicine of USC, Los Angeles, CA

T. Sourdille

11 Sanofi, Cambridge, MA, United States of America

J. Wang

11 Sanofi, Cambridge, MA, United States of America

D. S. Vagge

12 IQVIA, Bangalore, India

K. Kralova

13 Sanofi, Paris, France

F. Shafer

14 Sanofi, Bridgewater, NJ, United States of America

M. Wardecki

15 Sanofi, Warsaw, Poland

M. Lee

14 Sanofi, Bridgewater, NJ, United States of America

S. Berentsen

16 Department of Research and Innovation, Haugesund Hospital, Haugesund, Norway